Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review

Area of Science:

• Psychiatry
• Cardiology
• Pharmacology

Background:

• Schizophrenia significantly impacts daily functioning.
• Antipsychotic medications are linked to cardiovascular adverse effects, including arrhythmias and blood pressure changes.
• Sudden cardiac death is a leading global cause of mortality.

Purpose of the Study:

• To review the potential association between antipsychotic medications and sudden cardiac death.
• To examine the influence of prescribing patterns, such as polypharmacy, on cardiovascular events.
• To investigate the role of QTc interval prolongation in antipsychotic-associated cardiac risks.

Main Methods:

• This study is a narrative review of existing literature.
• It examines the relationship between antipsychotic drug use and cardiac side effects.
• The review considers concomitant medication use and its impact on cardiovascular events.

Main Results:

• Antipsychotic drugs are associated with an increased risk of ventricular arrhythmias and sudden cardiac death, potentially due to iatrogenic QTc interval prolongation.
• QTc prolongation and sudden cardiac death have been observed even with antipsychotic monotherapy.
• Concomitant use of QTc-prolonging drugs (e.g., opioids, antibiotics) may elevate this risk.

Conclusions:

• While antipsychotics and certain drug combinations may prolong the QTc interval, evidence does not definitively link this to predicting sudden cardiac death.
• The precise association between antipsychotic polypharmacy, QTc interval changes, and sudden cardiac death remains unclear.
• Further research is warranted to elucidate this potential association.